UK pharma major GSK (LSE: GSK) and US biotech SpringWorks Therapeutics are to end their collaboration combining Blenrep (belantamab mafodotin) and Ogsiveo (niro 11 June 2024
Gilead (Nasdaq: GILD) subsidiary Kite Pharma has announced updated four-year survival data from the ZUMA-3 study of Tecartus (brexucabtagene autoleucel). 5 June 2024
The market for branded multiple myeloma drugs is projected to grow to $33 billion by 2030, up from $23.5 billion in 2023, according to Bloomberg Intelligence (B 4 June 2024
The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Sarclisa (isatuximab) along 28 May 2024
Roche’s Japan-based subsidiary Chugai has launched PiaSky for injection 340 mg (crovalimab), a pH-dependent binding humanized anti-complement (C5) monoclonal an 23 May 2024
Diversified German drugmaker Bayer has reported group sales of 13.8 billion euros ($14.9 billion) for the first quarter, a fall of around 0.6%, meeting expectat 14 May 2024
Topline results from the Phase IIIa FRONTIER 2 trial show a positive treatment effect for Novo Nordisk’s (NOV: N) hemophilia A treatment Mim8. 14 May 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.